Resources from the same session
LBA1 - Denosumab added to 2 different nab-paclitaxel regimens as neoadjuvant therapy in patients with primary breast cancer: Time to event analysis from the GeparX 2 × 2 randomized clinical trial
Presenter: Sibylle Loibl
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
110MO - Statin use and early breast cancer survival: A Danish population-based cohort study using an emulated target trial approach
Presenter: Sixten Harborg
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
111MO - Tailored dose-dense versus standard adjuvant chemotherapy for high-risk early breast cancer: Efficacy outcomes and key subgroups after 10 years of follow-up in the randomized phase III PANTHER trial
Presenter: Theodoros Foukakis
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA1, 110MO and 111MO
Presenter: Elzbieta Senkus-Konefka
Session: Mini Oral session 2
Resources:
Slides
Webcast
268MO - Safety of vaginal estrogen therapy after early-stage breast cancer: A nationwide population-based target trial emulation
Presenter: Elise Dumas
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
269MO - The effects of exercise on sexual health and breast cancer-specific symptom burden in women with metastatic breast cancer: Results of the multinational randomized PREFERABLE-EFFECT trial
Presenter: Martina Schmidt
Session: Mini Oral session 2
Resources:
Abstract
Webcast
270MO - An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: Results of the validation study phase IV EORTC QLQ-BR42
Presenter: Vesna Bjelic-Radisic
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
Invited Discussant 268MO, 269MO and 270MO
Presenter: Matteo Lambertini
Session: Mini Oral session 2
Resources:
Slides
Webcast
112MO - Neoadjuvant study of 12 months of abemaciclib plus letrozole vs chemotherapy in HR+/HER2– highly proliferative (Ki67=20%) breast cancer: CARABELA (GEICAM/2019-01) trial
Presenter: Miguel Martin Jimenez
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
184MO - First-in-human phase I/IIa study of the first-in-class, next-generation CDK4-selective inhibitor PF-07220060 in combination with endocrine therapy (ET) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitors (CDK4/6i): Safety and efficacy update
Presenter: Timothy Yap
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast